ARTICLE | Clinical News
AG-881: Phase I started
July 20, 2015 7:00 AM UTC
Agios began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-daily oral AG-881 in about 150 patients. The companies partnered to develop and commercialize AG-881 worldwide (see BioC...